# Tirzepatide Side Effects: FDA Rates at Every Dose Level

> Tirzepatide side effects by dose, straight from the Zepbound and Mounjaro labels. Nausea rates, serious warnings, the birth control gap, and when to call.

URL: https://foundationmedicalwellness.com/tirzepatide-side-effects/
Author: Dr. Paul Frandsen
Published: 2026-09-10
Updated: 2026-09-10

Tirzepatide side effects are mostly digestive, and they cluster around dose increases. In the Zepbound weight trials, nausea reached 28% at 15 mg against 8% on placebo. Diarrhea hit 23%, vomiting 13%. Serious problems are uncommon, but a few deserve a same-day phone call.

![Tirzepatide side effects by dose at a glance](/images/blog/tirzepatide-side-effects/tirzepatide-side-effects-infographic.webp)

## What Are the Most Common Tirzepatide Side Effects?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Not a GLP-1. That's a real distinction, not a technicality, and it's the correction we make most often in the exam room. Tirzepatide acts on two gut hormone receptors rather than one, and both of those pathways slow the stomach down. Slower stomach emptying is where nearly every common side effect starts.

Eli Lilly sells the molecule under two names. Zepbound is approved for weight reduction and for moderate to severe obstructive sleep apnea. Mounjaro is approved for blood sugar control in type 2 diabetes. Same drug, two labels, two different trial populations.

Here are the numbers from the pooled Zepbound weight trials, which enrolled 2,519 adults for up to 72 weeks. Every figure comes from the [Zepbound prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) on DailyMed.

| Adverse reaction | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Constipation | 5% | 17% | 14% | 11% |
| Vomiting | 2% | 8% | 11% | 13% |
| Abdominal pain | 5% | 9% | 9% | 10% |
| Dyspepsia | 4% | 9% | 9% | 10% |
| Injection site reactions | 2% | 6% | 8% | 8% |
| Fatigue | 3% | 5% | 6% | 7% |
| Hair loss | 1% | 5% | 4% | 5% |
| Eructation (burping) | 1% | 4% | 5% | 5% |
| Reflux | 2% | 4% | 4% | 5% |
| Dizziness | 2% | 4% | 5% | 4% |
| Hypotension | 0% | 1% | 1% | 2% |

You're probably looking at that 28% and bracing. Fair enough. But read the placebo column first. Eight percent of adults who injected a dummy solution still reported nausea. Ordinary life makes stomachs unhappy, and some of what patients blame on a tirzepatide injection would have happened anyway.

Two rows surprise people. Constipation runs highest at the lowest dose and falls as the dose climbs, which is the opposite of what most patients expect. And nausea peaks at 10 mg rather than 15 mg, probably because the people who reach the top dose are the ones who tolerated the climb.

## Zepbound or Mounjaro: Does the Product Change What You Feel?

The molecule doesn't change. The population does, and so do the reported rates.

In the placebo-controlled Mounjaro trials for type 2 diabetes, nausea reached 18% at 15 mg against 4% on placebo. Diarrhea reached 17%. Decreased appetite came in at 11%, vomiting at 9%, and constipation at 7%. Every one of those sits below the matching figure in the weight trials.

| Reaction at 15 mg | Mounjaro (type 2 diabetes) | Zepbound (weight) |
|---|---|---|
| Nausea | 18% | 28% |
| Diarrhea | 17% | 23% |
| Vomiting | 9% | 13% |
| Constipation | 7% | 11% |
| Any GI reaction | 43.6% | 56% |
| Stopped for GI reasons | 6.6% | 4.3% |

Why the gap? Trial design, mostly. The diabetes studies ran shorter, used different comparison arms, and enrolled people whose stomachs had often already met metformin. None of that makes one product gentler than the other. In most cases it just means you can't read across two labels as if they were a head-to-head race.

Overall, gastrointestinal symptoms hit 56% of Zepbound patients at every maintenance dose against 30% on placebo. So roughly one in four people gets a digestive complaint that the medication caused rather than life.

## When Do Tirzepatide Side Effects Start and Stop?

Dose escalation drives the timeline. The [Zepbound label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) is specific: "The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks," and the steps after that rise by 2.5 mg with at least 4 weeks between them. Maintenance sits at 5 mg, 10 mg, or 15 mg.

The label is direct about the pattern: most nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time. In practice that means a wave of symptoms in the 2 to 4 days after each new dose, then a quieter stretch.

Our patients describe it as a staircase rather than a slope. In our experience, week one of a new dose is the hard week. By week three most of them forget they took anything. Which is why the ramp catches people off guard: they'd settled in, and then the next step resets it.

Severe reactions stayed rare. Severe gastrointestinal adverse reactions were reported in 1.7%, 2.5%, and 3.1% of patients at 5, 10, and 15 mg, against 1% on placebo. That is a real dose relationship, and it is why we rarely rush the ramp for someone who is already struggling.

Discontinuation tells the tolerability story better than any single symptom. Across both weight trials, 4.8%, 6.3%, and 6.7% of patients stopped permanently because of adverse reactions at the three maintenance doses, against 3.4% on placebo. Most of those exits happened in the first few months.

## Which Tirzepatide Side Effects Are Serious?

Common and serious are different questions. Here's the second list, the one worth reading twice.

![A physician in a white coat standing with a hand on the shoulder of a man in a mustard polo seated on the exam table](/images/blog/tirzepatide-side-effects/tirzepatide-side-effects-inline-1.webp)

**Acute pancreatitis.** In the pooled weight trials, adjudicated acute pancreatitis occurred in 0.2% of tirzepatide patients and 0.2% of placebo patients. In the diabetes program the rates were 0.23 versus 0.11 per 100 years of exposure. The signal is small. The consequence is not, so persistent severe abdominal pain that may radiate to the back means stop the drug and get seen.

**Gallbladder problems.** Rapid weight loss is hard on a gallbladder. Cholelithiasis was reported in 1.1% of Zepbound patients versus 1% on placebo, cholecystitis in 0.7% versus 0.2%, and gallbladder removal in 0.2% versus none on placebo. Right upper belly pain after fatty meals is the classic story.

**Kidney injury from dehydration.** There have been postmarketing reports of acute kidney injury, some requiring dialysis. Almost all followed vomiting or diarrhea that nobody replaced with fluids. This one is largely preventable.

**Severe allergic reaction.** Immediate hypersensitivity reactions occurred in 2.1% of Zepbound patients against 0.4% on placebo, and severe reactions in 0.1% against none. Anaphylaxis and angioedema have been reported after approval. Swelling of the face, lips, or throat is an emergency.

**Thyroid C-cell tumors.** Tirzepatide carries a boxed warning. In rats, the drug caused dose-dependent thyroid tumors. Whether that translates to thyroid cancer in people is unknown. The medication is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

**Bowel obstruction and ileus.** Postmarketing reports include ileus, intestinal obstruction, and severe constipation with fecal impaction. Constipation that turns into no bowel movement plus vomiting is not a laxative problem anymore.

## Does Tirzepatide Affect Birth Control?

Here's the thing: this one gets missed constantly, and it's specific to tirzepatide rather than the whole class.

Slowed stomach emptying reduces how much of an oral contraceptive gets absorbed. In testing, a single 5 mg dose of tirzepatide cut peak ethinyl estradiol levels by 59%. The prescribing information asks patients using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose escalation.

Non-oral hormonal contraception is not affected. Neither is an IUD.

Honestly, this is the counseling point we see skipped most often by online prescribers. A patient on a weight loss medication who was not planning a pregnancy deserves to hear it before the first injection, not after.

## Can Tirzepatide Cause Low Blood Sugar?

On its own, rarely. In combination, yes.

In the Zepbound trial that enrolled adults with type 2 diabetes, blood glucose below 54 mg/dL was reported in 4.2% of treated patients against 1.3% on placebo. Add a sulfonylurea and the figure jumped to 10.3%, compared with 2.1% for patients not taking one. Insulin raises the risk the same way.

If you take insulin or a sulfonylurea, your prescriber should be planning a dose adjustment for those medications before tirzepatide treatment starts. Waiting to see what happens is not a plan. Hypoglycemia has also been reported in adults without diabetes, so keeping your blood sugar levels steady with regular protein still matters.

## What About Hair Loss, Blood Pressure, and Fatigue?

Three complaints that patients raise often and rarely find answered well. So, briefly.

**Hair loss.** Reported in about 5% of Zepbound patients against 1% on placebo, and it splits sharply by sex: 7.1% of women versus 0.5% of men on the drug. The label ties it to the weight reduction itself rather than to the molecule. It is usually telogen effluvium, the shedding that follows any rapid change, and it usually recovers. No patient in the trials stopped treatment because of it.

**Low blood pressure.** Hypotension occurred in 1.6% of Zepbound patients against 0.1% on placebo, and it was more common in people already taking blood pressure medication, at 2.2% versus 1.2%. If you take an antihypertensive and lose 15% of your body weight, your old dose may now be too much. That is a good problem attached to a real dizziness risk.

**Fatigue.** Reported in 5% to 7% across doses against 3% on placebo. Some of it is the medication. Actually, that undersells the other half: a lot of it is eating far less than you used to without adjusting protein or fluids, and that part is fixable.

## Who Should Avoid Tirzepatide?

The contraindications are short. The cautions are longer.

- A personal or family history of medullary thyroid carcinoma, or MEN 2 syndrome.
- A previous serious allergic reaction to tirzepatide or anything in the formulation.
- Severe gastroparesis, where the label says the medication is not recommended.
- Active pancreatitis, or a history that a prescriber has not reviewed.
- Pregnancy, or a pregnancy you are actively planning.
- A history of diabetic retinopathy, which needs monitoring rather than a flat no.

One more that belongs on every pre-op checklist. Because tirzepatide delays gastric emptying, there have been rare reports of stomach contents reaching the lungs during general anesthesia or deep sedation, even after normal fasting. Tell your surgeon and your anesthesiologist you take it. Every time.

## What Actually Helps During the Ramp?

Practical measures, mostly. Honestly, none of this is exotic, and it works better than waiting it out.

![A physician in a white coat seated opposite a woman in a sage green top, the two turned toward each other in rust armchairs by a wide window](/images/blog/tirzepatide-side-effects/tirzepatide-side-effects-inline-2.webp)

1. **Eat smaller and earlier.** A full plate on a slow stomach is the most reliable way to trigger nausea.
2. **Front-load protein.** Aim for it at the first meal of the day, when appetite is usually highest.
3. **Drink between meals rather than during.** Fluid volume plus food volume is what tips people over.
4. **Cut the fat content of the meal after your injection.** Fatty food lingers, and lingering is the problem.
5. **Treat constipation early.** Fiber, fluid, and a stool softener beat a week of straining.
6. **Ask about staying at a dose.** There is no rule that says you must reach 15 mg.

That last point matters more than the rest combined. The label itself says to consider treatment response and tolerability when choosing the maintenance dose. But patients rarely hear it that way. They hear 15 mg as a target, and from what we've seen a patient doing well at 7.5 mg has no obligation to climb.

## Did the FDA Change the Tirzepatide Label?

Yes, several times, and the changes run in both directions.

The current label was revised in August 2026. Its own list of recent major changes shows the section on suicidal behavior and ideation was removed in February 2026, after the class-wide review found no consistent signal. The severe gastrointestinal warning was updated the same month. Diabetic retinopathy guidance was revised in August 2026.

Zepbound also gained a second indication (moderate to severe obstructive sleep apnea in adults with obesity), and that brought its own safety data. Pancreatitis rates in the sleep apnea trials ran higher than in the weight trials, at 0.84 per 100 years of exposure against none on placebo.

Labels move. If you were prescribed tirzepatide in 2024, the leaflet in your drawer is out of date.

## How Do Tirzepatide Side Effects Compare With Semaglutide?

Two answers, and they point different ways.

On effectiveness, there is a genuine head-to-head. SURMOUNT-5 randomized 751 adults with obesity and no diabetes to maximum tolerated tirzepatide or maximum tolerated semaglutide for 72 weeks. Average weight change was 20.2% with tirzepatide against 13.7% with semaglutide. The [trial report](https://pubmed.ncbi.nlm.nih.gov/40353578/) notes that gastrointestinal events were the most common adverse events in both groups, mostly mild to moderate, and concentrated during dose escalation.

On tolerability, the comparison is looser. We compared the two labels row by row rather than relying on one study, and across the separate FDA trials nausea reached 44% on semaglutide 2.4 mg and 28% on tirzepatide 15 mg. Different trials, different populations, so read that as a rough guide rather than a verdict. Our full [semaglutide vs tirzepatide](/semaglutide-vs-tirzepatide/) comparison covers dosing and cost alongside tolerability, and our [GLP-1 side effects](/glp-1-side-effects/) guide puts all four drugs in one table.

What about compounded tirzepatide? The same molecule brings the same possible side effects, plus a variable we cannot verify. Compounded products skip the FDA review for purity and potency, and dosing instructions differ between pharmacies. When a patient reports symptoms that don't match the label pattern, the compounded vial is the first thing we ask about.

## When Should You Seek Medical Attention?

Some symptoms wait for your next visit. These do not.

- Severe abdominal pain that persists, especially spreading to the back.
- Vomiting or diarrhea you cannot keep ahead of, or no urine for most of a day.
- Right upper belly pain after eating, with fever or yellowing of the eyes.
- Swelling of the face, lips, tongue, or throat, or trouble breathing.
- A lump in the neck, trouble swallowing, or a hoarse voice that stays.
- Blood sugar below 54 mg/dL, or shakiness and confusion that food fixes slowly.
- No bowel movement for several days along with vomiting.

Anything on that list is a reason for immediate medical attention. Call our clinic or go to an emergency department. Do not wait to see whether the next dose feels better.

## How We Manage Tirzepatide Side Effects at Foundation Wellness

We slow down more than most. Our starting assumption is that the ramp is where patients quit, so we plan for it in advance rather than reacting to a worried text message on day three. The first question our patients ask is almost never about cost. It is about nausea, and how bad it gets.

Before the first tirzepatide injection our team reviews thyroid history, pancreatitis history, gallbladder history, current blood pressure medications, and contraception. That last one takes 30 seconds and prevents the problem nobody wants to discover later.

Then we check in during each escalation week rather than at the end of the month. Most of the adverse effects we see are manageable with a meal change, a fluid target, or an extra 4 weeks at the current dose. Unfortunately, patients who buy a plan online and get no contact until the next shipment tend to stop the medication instead.

We are in American Fork and we see patients from across Utah County and the Wasatch Front, in person and by telehealth. If you want the program detail first, read about our [GLP-1 injections in Utah](/glp-1-injections-utah/) or our [weight optimization program](/services/weight-optimization/). Then [reach out](/contact/) when you are ready.

This article is general information about tirzepatide side effects. It is not medical advice. Talk with a licensed healthcare provider about your own history before starting or stopping any medication.

## Frequently Asked Questions

### How long do tirzepatide side effects last?

Usually days, not months. The label reports that most nausea, vomiting, and diarrhea happened during dose escalation and decreased over time. A fresh wave after each increase, settling within about a week, is the pattern we see most.

### Does tirzepatide affect birth control?

It can. Delayed stomach emptying lowered the absorption of an oral contraceptive in testing. The label asks patients using oral birth control to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and 4 weeks after each dose increase.

### Which tirzepatide side effects need a same-day call?

Severe abdominal pain that will not settle, especially with vomiting. Also vomiting or diarrhea you cannot keep ahead of, right upper belly pain after meals, and any swelling of the face, lips, or throat. Those need medical attention now, not at your next visit.

### Are tirzepatide side effects worse than semaglutide?

In the FDA trials, tirzepatide reported lower digestive rates than semaglutide at full weight-management doses. Those came from separate trials, so the gap is a rough guide. Individual tolerance varies more than the averages suggest.

### Do tirzepatide side effects mean the dose is too high?

Not necessarily. A fresh wave of gastrointestinal symptoms in the days after an increase is expected and usually settles. Symptoms that keep worsening across a full 4 weeks at one dose are a different message, and that is when we hold or step back.

### Can you switch from semaglutide to tirzepatide to escape side effects?

Sometimes it helps, though a switch restarts dose escalation at the bottom. You get a different side effect profile rather than an exit from side effects. Patients who reacted badly to one drug at full dose often do fine on the other at a middle dose.

### Do side effects come back if you stop and restart?

Usually yes. Tolerance to the gastrointestinal effects fades within a few weeks off the drug, so a restart after a long gap often means repeating the ramp. Tell your prescriber how long the gap was rather than resuming at your old dose.

## Key Takeaways

- Tirzepatide side effects are mostly digestive, with nausea at 28%, diarrhea at 23%, and vomiting at 13% at the 15 mg Zepbound dose against 8%, 8%, and 2% on placebo.
- Roughly 56% of patients reported a gastrointestinal reaction at every maintenance dose, against 30% on placebo.
- Symptoms cluster in the days after each dose increase and settle over time, which is why holding a dose is a legitimate option.
- Between 4.8% and 6.7% of trial patients stopped permanently because of adverse reactions, compared with 3.4% on placebo.
- Serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and a boxed warning about thyroid tumors seen in rats.
- Oral birth control needs a backup method for 4 weeks after starting and after each increase, a detail that gets skipped often.
- The label changed in 2026, removing the suicidal behavior section and updating gastrointestinal and retinopathy guidance.
- At Foundation Wellness we check in during escalation weeks rather than monthly, because that is where patients quit.

## Sources

- U.S. Food and Drug Administration, [Zepbound (tirzepatide) prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b), sections 5, 6, 7 and 8, revised August 2026.
- U.S. Food and Drug Administration, [Mounjaro (tirzepatide) prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0), sections 5 and 6, revised August 2026.
- Aronne LJ et al., [Tirzepatide as Compared with Semaglutide for the Treatment of Obesity](https://pubmed.ncbi.nlm.nih.gov/40353578/), New England Journal of Medicine, 2025 (SURMOUNT-5).
- National Institute of Diabetes and Digestive and Kidney Diseases, [prescription medications to treat overweight and obesity](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity).
- U.S. Food and Drug Administration, [medicines containing semaglutide](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss), for comparison of compounded product oversight.

---

Source: https://foundationmedicalwellness.com/tirzepatide-side-effects/
Clinic: 456 E State Street, Suite 1400, American Fork, UT 84003
Phone: (800) 983-1974